Has Bidhan Das, MD received payments from drug or device companies?

Yes. Drug and device makers reported $349,659 in general payments to Bidhan Das, MD across 561 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Bidhan Das, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Bidhan Das, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Bidhan Das, MD

Colon & Rectal Surgery · Sugar Land, TXNPI 1881832145

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Merck at 25.4% of the total. Among colon & rectal surgery clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$349,659in general payments, 2019–2025

Across 561 payments — averaging $623.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$89K
Mimedx Group, Inc.$83K
Vertex$38K
Pacira Pharmaceuticals Incorporated$37K
Medtronic$35K
Convatec Inc.$18K
plus $51K from 34 others

What the payments were for

Consulting fees$83,55924%
Speaking & faculty fees$190,44454%
Travel & lodging$57,23016%
Food & beverage$18,4255%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	128	$88,954
Mimedx Group, Inc.	45	$82,730
Vertex	47	$37,999
Pacira Pharmaceuticals Incorporated	54	$36,625
Medtronic(2 entities)	141	$34,505
Convatec Inc.	17	$17,727
Biom'up France SAS	13	$13,125
Biom'up SA	18	$10,185
Suture Ease, Inc.	2	$10,074
Johnson & Johnson	3	$6,968
Ethicon Endo-surgery Inc.	3	$4,743
Medical Device Business Services, Inc.	5	$1,825
GI Supply, Inc.	1	$507
Romark Laboratories, LC	22	$454
TELA Bio, Inc.	8	$400
Covidien LP	1	$325
Shire North American Group Inc	9	$265
Intuitive Surgical	3	$251
Baxter Healthcare	3	$224
Axonics, Inc.	4	$180
Smith+Nephew	2	$166
THD America, Inc.	1	$162
Activ Surgical, Inc.	1	$144
Acera Surgical, Inc.	1	$142
Davol Inc.	1	$140
Baudax Bio Inc.	2	$129
Takeda Pharmaceuticals U.S.A., Inc.	5	$117
Heron Therapeutics, Inc.	1	$111
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	7	$107
Stryker	1	$106
Braintree Laboratories, Inc.	2	$44
Ferring Pharmaceuticals Inc.	2	$41
AbbVie	1	$35
Boston Scientific	1	$28
Integra Lifesciences Corporation	1	$28
Wound Management Technologies, Inc	1	$24
Trevena, Inc.	1	$23
Olympus America Inc.	1	$19
Coopersurgical, Inc.	1	$17
Kerecis Limited	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$349,659 in reported general payments places this provider in the 95th percentile of 200 colon & rectal surgery providers in Texas.

See all colon & rectal surgery providers in Texas →

Medicare billing

Part B allowed, 2024

$157,384

Medicare patients

284

Services billed

910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates	50	$3,256
Enoxaparin Sodium	14	$1,807
Budesonide DrBudesonide	13	$1,268
Ciprofloxacin Hcl	48	$334
Metronidazole	75	$291
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl	19	$234
Neomycin Sulfate	31	$165
Methocarbamol	21	$163
Ketorolac Tromethamine	11	$138

Paid to pharmacies, not to this prescriber.

Other colon & rectal surgery in Sugar Land

Amit AgarwalSugar Land$90K
Thiru LakshmanAustin$756K
Diego Marines CopadoHouston$462K
Christopher de JesusSan Antonio$201K
Farshid AraghizadehFort Worth$181K
Jefferson HurleyIrving$163K
Erik AskenasyHouston$142K
Eric HaasHouston$140K
Robert JacobsonDallas$125K
Theodoros VoloyiannisHouston$100K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →